CY1111740T1 - Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων - Google Patents

Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων

Info

Publication number
CY1111740T1
CY1111740T1 CY20111100737T CY111100737T CY1111740T1 CY 1111740 T1 CY1111740 T1 CY 1111740T1 CY 20111100737 T CY20111100737 T CY 20111100737T CY 111100737 T CY111100737 T CY 111100737T CY 1111740 T1 CY1111740 T1 CY 1111740T1
Authority
CY
Cyprus
Prior art keywords
trp
missing
phe
lys
amino acid
Prior art date
Application number
CY20111100737T
Other languages
English (en)
Inventor
Bjarne Due Larsen
Jorgen Soberg Petersen
Daniel R Kapusta
Kenneth William Harlow
Original Assignee
Serodus Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus Asa filed Critical Serodus Asa
Publication of CY1111740T1 publication Critical patent/CY1111740T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Αποκαλύπτεται μια ποικιλία συζευγμάτων πεπτιδίων που αναπαρίστανται από τον ακόλουθο γενικό χημικό τύπο (I): R1-Z-X-Z΄-R2, όπου το Χ αναπαριστά ένα εξαπεπτίδιο του γενικού χημικού τύπου (II): A1-A2-A3-A4-A5-A6 όπου το Α1 αναπαριστά Arg, Lys, ή His, το Α2 αναπαριστά Tyr, Trp ή Phe, το Α3 αναπαριστά Tyr, Asn, Trp ή Phe, το Α4 αναπαριστά Lys, Arg ή His, το Α5 αναπαριστά Phe, Tyr, Trp, Leu, Val ή Ιle, και το Α6 αναπαριστά Arg, Lys, ή His και όπου το κάθε ένα κατάλοιπο αμινοξέος στο εν λόγω εξαπεπτίδιο μπορεί να είναι στην L ή D μορφή· το Ζ αναπαριστά μια άλυσο φορτισμένου πεπτιδίου από 4 έως 20 κατάλοιπα αμινοξέων έχοντας την D ή L χωροδιάταξη ή λείπει˙ και το Ζ̕ αναπαριστά μια άλυσο φορτισμένου πεπτιδίου από 4 έως 20 κατάλοιπα αμινοξέων έχοντας την D ή L χωροδιάταξη ή λείπει, παρεχομένου του γεγονότος ότι δεν λείπουν αμφότερα τα Ζ και Ζ'· το R1 αναπαριστά Η ή μια ακυλομάδα· το R2 αναπαριστά NR3R4 όπου το κάθε ένα εκ των R3 και R4 αναπαριστά ανεξαρτήτως υδρογόνο, C(1-6)αλκοξυομάδα, αρυλοξυομάδα, ή ένα κατώτερο αλκύλιο ως ορίζεται εις το παρόν· ή το R2 αναπαριστά ΟΗ· τα δε συζεύγματα πεπτιδίων του χημικού τύπου (I) όντας προαιρετικώς και περαιτέρω συνδεδεμένα σε μια οντότητα μεταφοράς· και τα άλατα, ένυδρα άλατα και επιδιαλυτωμένα άλατα εξ αυτών, και τα C-τελικώς αμιδομένα ή εστεροποιημένα παράγωγα εξ αυτών με κατάλληλα οργανικά ή ανόργανα οξέα, συμπεριλαμβανομένων των μεθόδων παρασκευής τέτοιων συζευγμάτων. Παρέχονται επίσης και αντισώματα που δεσμεύονται συγκεκριμένα στα συζεύγματα πεπτιδίων. Η παρούσα εφεύρεση έχει ένα ευρύ φάσμα σημαντικών εφαρμογών συμπεριλαμβανομένης της χρήσης στην αγωγή διαταραχών που επηρεάζονται από την νοσισεπτίνη και τα σχετικά παρόμοια με οπιοειδή πεπτίδια.
CY20111100737T 2000-06-16 2011-07-28 Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων CY1111740T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000944 2000-06-16
DKPA200001485 2000-10-05
US25167100P 2000-12-06 2000-12-06
EP01952155A EP1294746B1 (en) 2000-06-16 2001-06-15 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains

Publications (1)

Publication Number Publication Date
CY1111740T1 true CY1111740T1 (el) 2015-10-07

Family

ID=27222400

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100737T CY1111740T1 (el) 2000-06-16 2011-07-28 Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων

Country Status (8)

Country Link
EP (1) EP1294746B1 (el)
JP (1) JP4624639B2 (el)
AT (1) ATE508138T1 (el)
AU (1) AU7294401A (el)
CA (1) CA2410224C (el)
CY (1) CY1111740T1 (el)
DE (1) DE60144561D1 (el)
WO (1) WO2001098324A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550425B2 (en) 2000-06-16 2009-06-23 Zealand Pharma A/S Diuretic peptide conjugates
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
WO2003030828A2 (en) * 2001-10-09 2003-04-17 Synvax, Inc. Nociceptin-based analgesics
WO2003097857A2 (en) * 2002-05-17 2003-11-27 Zealand Pharma A/S Method for the detection of aquaretic compounds
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ,インコーポレイテッド 腎症の治療および予防のための組成物
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012065082A1 (en) * 2010-11-11 2012-05-18 Massachusetts Institute Of Technology Dendrimer-based excipients for the attentuation of protein aggregation
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
KR20160023669A (ko) 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US20160235807A1 (en) 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CN103936838B (zh) * 2014-04-10 2015-10-28 武汉启瑞科技发展有限公司 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用
GB201506380D0 (en) 2015-04-15 2015-05-27 Serodus Asa Materials and methods for treatment of pulmonary hypertension
JP2024513651A (ja) * 2021-02-26 2024-03-27 ニューヨーク ユニバーシティ 共有結合性ペプチドコンジュゲートに結合する抗体を含む組成物及び方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
AU2712999A (en) * 1998-03-05 1999-09-20 Novo Nordisk A/S Use of hexapeptides for the manufacture of a pharmaceutical composition for the treatment of hot flushes
NZ506839A (en) * 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CN1981873A (zh) * 2000-06-09 2007-06-20 莱古伦公司 制备微胶粒的方法和所述微胶粒的用途
US7459539B2 (en) * 2000-12-15 2008-12-02 Agensys, Inc. Antibody that binds zinc transporter protein 108P5H8

Also Published As

Publication number Publication date
CA2410224A1 (en) 2001-12-27
EP1294746B1 (en) 2011-05-04
CA2410224C (en) 2013-08-13
AU7294401A (en) 2002-01-02
JP2004516811A (ja) 2004-06-10
EP1294746A1 (en) 2003-03-26
DE60144561D1 (de) 2011-06-16
JP4624639B2 (ja) 2011-02-02
WO2001098324A8 (en) 2002-03-21
WO2001098324A1 (en) 2001-12-27
ATE508138T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
CY1111740T1 (el) Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων
ES2194861T3 (es) Peptidos opiodes.
TW251274B (el)
EP0299402A3 (en) Lhrh antagonists, their manufacture and pharmaceutical clhrh antagonists, their manufacture and pharmaceutical compositions thereof ompositions thereof
ZA919387B (en) Bombesin antagonists
AU759442B2 (en) Novel LHRH antagonists with improved solubility characteristics
GB1570210A (en) Peptides
NZ335879A (en) Somatostatin antagonist peptides having a D-amino acid at the second residue
DK0745093T3 (da) Hidtil ukendte oligopeptoder med affinitet til opioidreceptorer
US4087419A (en) Heptapeptides and methods for their production
CA1181395A (en) Lh-rh antagonists
CS207570B2 (en) Method of making the tetradecapeptide
KR870007206A (ko) 폴리펩타이드 화합물
IT1256247B (it) Peptidi ciclici
KR850006940A (ko) 레닌 억제제의 제조방법